Global High-Priority Regulatory Events — January 31, 2026

Revenue accelerated 45% YoY to $150M (vs sector avg 12%), gross margins expanded 250 bps QoQ to 65%, IPO proceeds earmarked for R&D

CEO purchased $5M shares pre-IPO lockup, holdings now 15% stake, signaling strong management conviction amid 30% QoQ user growth

Guidance raised FY2026 revenue to $300M (+60% YoY), up from prior $250M, with EBITDA target $80M; roadshow starts Feb 10

Debt-to-equity ratio improved to 0.2x from 0.5x YoY, no buybacks but $100M capex planned post-IPO

Revenue contracted 28% YoY to $120M, same-facility volumes down 22% QoQ, operational cash burn $15M/quarter

CFO sold 60% holdings ($1.2M) in last 30 days post-insolvency filing, total insider sales $3M YTD

Gross margins compressed 450 bps QoQ to 28%, ROE deteriorated to -15% from -5% YoY amid rising input costs

Dividend suspended (first cut in 10 years, prior yield 4%), no buybacks, $300M debt pledged as collateral

Forward P/E at IPO 20x vs sector 28x, backlog grew 40% YoY to $400M, capacity utilization 85%

Net debt/EBITDA spiked to 8x from 4x YoY, liquidity ratio 0.6x (down QoQ), guidance suspended

Unknown's 65% margins outperform Cian's 28% by 37 pts, highlighting relative growth resilience

Chapter 11 filing with $300M debt (75% secured), creditor claims exceed assets by $100M, restructuring timeline 12-18 months

Revenue -28% YoY for 3rd straight quarter, EBITDA loss widened to -$20M from -$8M YoY

4 executives sold $4.5M shares in 60 days pre-filing, holdings down 40% YTD, no buys

Dividend cut 100%, buyback program canceled (previously $50M authorized), capex slashed 60% YoY

Pricing risk with $22-26 range, bookrunner cuts noted in S-1/A, potential 15% discount if demand softens

Customer concentration 40% top-3 (up QoQ), supply chain costs +20% YoY despite margin gains

Current ratio 0.8x (down from 1.5x YoY), $50M revolver fully drawn, covenant breaches flagged

FY2026 targets assume 20% market share gain, sensitive to macro slowdown per risk factors

$500M raise at 20x forward P/E (sector 28x), 60% YoY growth guidance, post-IPO pop potential 25% based on peers

CEO $5M buy + lockup, user metrics +30% QoQ, undervalued vs comps at 8x sales

Insolvency with -28% YoY revenue, insider dumping, trading at 1.2x book (peers 2.5x), downside 40% to liquidation value

Post-IPO $100M capex for 50% capacity boost, utilization 85% (peers 70%), margin tailwind 200 bps

Restructuring may yield asset sales ($200M facilities), debt-to-equity post-reorg <2x, if creditor deal by Q2

Outperforms Cian margins by 37 pts, backlog $400M covers 2.5yrs revenue, enter pre-IPO secondary

Senior debt trading 60cts/dollar, 12% yield pickup vs peers, recovery potential 80% in 18 months

Roadshow Feb 10-15, listing Feb 25, earnings Mar 5 with guidance reaffirm

1/2 events bullish IPO growth (45% YoY revenue) vs 1 insolvency (-28% YoY), implying selective alpha in high-conviction listings amid bankruptcies

Cian Healthcare -450 bps QoQ compression (to 28%), tied to volumes -22%, signaling sector cost pressures vs broad market +100 bps avg

No sales at Unknown (CEO buy $5M) vs Cian $4.5M dumps, pattern flags conviction in growth vs concern in distress names

Cian dividend suspension +60% capex cut contrasts Unknown's reinvestment, trend shows healthy firms hoarding for M&A

Raised targets at Unknown (+20% to $300M) vs suspended at Cian, portfolio implication: overweight guided growth plays

Monitor pricing feedback Feb 10-15, potential guidance tweak or size increase [Feb 15]

Watch debut volatility Feb 25, insider lockup expiration Q4 2026 for selling pressure

Key restructuring terms, vote on DIP financing $40M, risk of conversion to Ch7 [Feb 20]

Track further Form 4 sales post-filing, threshold >10% holdings change

Post-IPO Q4 results Mar 5, reaffirm 60% FY2026 growth amid macro check

Monitor Q1 auctions of $200M facilities, bid activity for dip-buy opportunities

SEC comments on S-1/A resolution by Feb 5, delay risk to timeline